<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>482</serviceExecutionTime><Drug id="16159"><DrugName>romosozumab</DrugName><DrugNamesKey><Name id="43095864">Evenity</Name><Name id="42959249">romosozumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>anti-SOST1 FAb-PEG</Value></Name><Name><Value>osteoporosis therapeutics, Celltech/Amgen</Value></Name><Name><Value>BEER targeted therapeutics, Celltech/Amgen</Value></Name><Name><Value>SOST targeted therapeutics, Celltech/Amgen</Value></Name><Name><Value>anti-sclerostin therapeutics, Celltech/Amgen</Value></Name><Name><Value>sclerostin-targeting antibody fragment, Celltech/Amgen</Value></Name><Name><Value>sclerostin-targeting monoclonal antibody (osteoporosis), Celltech/Amgen</Value></Name><Name><Value>sclerostin-targeting antibody fragment, UCB Celltech/Amgen</Value></Name><Name><Value>CDP-7851</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Sclerostin Ab</Value></Name><Name><Value>Sclerostin antibody</Value></Name><Name><Value>AMG-785</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>romosozumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Evenity</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>rinisizynab</Value></Name><Name><Value>romosozumab-aqqg</Value></Name></DrugSynonyms><CompanyOriginator id="15336">UCB Celltech</CompanyOriginator><CompaniesPrimary><Company id="14109">Amgen Inc</Company><Company id="1089961">Amgen Astellas BioPharma KK</Company><Company id="15336">UCB Celltech</Company></CompaniesPrimary><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="20452">UCB SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16159" type="Drug"><TargetEntity id="446781" type="siDrug">Romosozumab</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1089961" type="Company"><TargetEntity id="5040256979" type="organizationId">Amgen Astellas BioPharma KK</TargetEntity></SourceEntity><SourceEntity id="14109" type="Company"><TargetEntity id="4295905537" type="organizationId">Amgen Inc</TargetEntity></SourceEntity><SourceEntity id="15336" type="Company"><TargetEntity id="5035523587" type="organizationId">UCB Celltech (UK Branch)</TargetEntity></SourceEntity><SourceEntity id="20452" type="Company"><TargetEntity id="4295859381" type="organizationId">Ucb SA</TargetEntity></SourceEntity><SourceEntity id="1091" type="ciIndication"><TargetEntity id="10017076" type="MEDDRA"></TargetEntity><TargetEntity id="D050723" type="MeSH"></TargetEntity><TargetEntity id="-1417017400" type="omicsDisease"></TargetEntity><TargetEntity id="1166" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="246" type="ciIndication"><TargetEntity id="10031282" type="MEDDRA"></TargetEntity><TargetEntity id="D010024" type="MeSH"></TargetEntity><TargetEntity id="-1487907849" type="omicsDisease"></TargetEntity><TargetEntity id="965" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2549" type="ciIndication"><TargetEntity id="M81.0" type="ICD10"></TargetEntity><TargetEntity id="10031285" type="MEDDRA"></TargetEntity><TargetEntity id="D015663" type="MeSH"></TargetEntity><TargetEntity id="-67845500" type="omicsDisease"></TargetEntity><TargetEntity id="966" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="45" type="ciIndication"><TargetEntity id="10005956" type="MEDDRA"></TargetEntity><TargetEntity id="D001847" type="MeSH"></TargetEntity><TargetEntity id="-259255056" type="omicsDisease"></TargetEntity><TargetEntity id="962" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="16646" type="Action"><TargetEntity id="3186" type="Mechanism">Anti-Sclerostin</TargetEntity></SourceEntity><SourceEntity id="445" type="Action"><TargetEntity id="6007" type="Mechanism">Osteogenesis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-04172" type="ciTarget"><TargetEntity id="509640" type="siTarget">Sclerostin</TargetEntity><TargetEntity id="-870654501" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Male osteoporosis - Japan - Mar-2019</FirstLaunched><FirstLaunched>Osteoporosis - Japan - Mar-2019</FirstLaunched><FirstLaunched>Postmenopausal osteoporosis - Japan - Mar-2019</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="246">Osteoporosis</Indication><Indication id="2548">Male osteoporosis</Indication><Indication id="2549">Postmenopausal osteoporosis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1091">Bone injury</Indication><Indication id="45">Bone disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="16646">Sclerostin inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="445">Bone synthesis stimulator</Action><Action id="89">Bone resorption inhibitor</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="807">Monthly dosing</Technology></Technologies><LastModificationDate>2019-07-01T14:09:54.000Z</LastModificationDate><ChangeDateLast>2019-07-02T00:00:00.000Z</ChangeDateLast><AddedDate>1997-10-13T11:43:22.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14109" linkType="Company"&gt;Amgen&lt;/ulink&gt;, under license from and in collaboration with &lt;ulink linkID="15336" linkType="Company"&gt;UCB Celltech&lt;/ulink&gt; (formerly  Celltech) and in collaboration with Japanese licensee, &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas Pharma&lt;/ulink&gt; (via its Japanese joint venture &lt;ulink linkID="1089961" linkType="Company"&gt;Amgen Astellas Biopharma&lt;/ulink&gt;), has developed and launched romosozumab (romosozumab-aqqg; CDP-7851, Sclerostin Ab, AMG-785, Evenity, rinisizynab), an injectable sclerostin-neutralizing humanized mAb that stimulates bone formation     [&lt;ulink linkID="248274" linkType="Reference"&gt;248274&lt;/ulink&gt;], [&lt;ulink linkID="451519" linkType="Reference"&gt;451519&lt;/ulink&gt;]. The product is indicated in the US for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [&lt;ulink linkID="2139880" linkType="Reference"&gt;2139880&lt;/ulink&gt;]. In Japan, the drug is indicated for the treatment of osteoporosis  in patients at high risk of fracture  [&lt;ulink linkID="2109509" linkType="Reference"&gt;2109509&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, the drug was launched in Japan for osteoporosis [&lt;ulink linkID="2125293" linkType="Reference"&gt;2125293&lt;/ulink&gt;].  In April 2019, the drug was launched in the US for postmenopausal osteoporosis   [&lt;ulink linkID="2141567" linkType="Reference"&gt;2141567&lt;/ulink&gt;]. By January 2018, an MAA had been filed  for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture [&lt;ulink linkID="1995572" linkType="Reference"&gt;1995572&lt;/ulink&gt;]; in June 2019, the CHMP adopted a negative opinion on the MAA for the treatment of severe osteoporosis; the companies planned to request re-examination [&lt;ulink linkID="2168818" linkType="Reference"&gt;2168818&lt;/ulink&gt;], [&lt;ulink linkID="2169105" linkType="Reference"&gt;2169105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Romosozumab was previously being developed for the potential treatment of acceleration of bone healing. In July 2009, a phase II trial had begun [&lt;ulink linkID="1017284" linkType="Reference"&gt;1017284&lt;/ulink&gt;]. However, In February 2013, UCB reported that a phase III program in the acceleration of fracture healing would not be pursued based on available phase II data and general regulatory guidance on fracture healing programs. The company also noted that safety was not a factor in the decision  [&lt;ulink linkID="1375281" linkType="Reference"&gt;1375281&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Patent coverage for romosozumab relating to polypeptides in both the US and EU expires in 2026 [&lt;ulink linkID="1528539" linkType="Reference"&gt;1528539&lt;/ulink&gt;], [&lt;ulink linkID="1900450" linkType="Reference"&gt;1900450&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In July 2016, Amgen filed a BLA based on data from the FRAME study for approval for PMO [&lt;ulink linkID="1782080" linkType="Reference"&gt;1782080&lt;/ulink&gt;].  In September 2016, the FDA accepted the BLA  [&lt;ulink linkID="1799303" linkType="Reference"&gt;1799303&lt;/ulink&gt;]. However in May 2017 a cardiovascular safety signal was observed in the ARCH study [&lt;ulink linkID="1929292" linkType="Reference"&gt;1929292&lt;/ulink&gt;].  In July 2017, Amgen received a Complete Response Letter from the FDA for the BLA for PMO with the request to resubmit  the BLA with the inclusion of data from the phase III BRIDGE study in male osteoporosis and the &lt;ulink linkID="2472" linkType="Drug"&gt;alendronate&lt;/ulink&gt;-active comparator ARCH study; the FDA granted 12 months to respond with the requested data  [&lt;ulink linkID="1945412" linkType="Reference"&gt;1945412&lt;/ulink&gt;], [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. In February 2018,  UCB noted that the drug was under regulatory review in the US and a comprehensive assessment of the cardiovascular safety  was ongoing [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. In July 2018, a BLA was resubmitted to the FDA, adding clinical trial data from the  BRIDGE and ARCH studies to the originally submitted FRAME data [&lt;ulink linkID="2053645" linkType="Reference"&gt;2053645&lt;/ulink&gt;]; in November 2018, the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) planned to review the BLA on January 16, 2019 [&lt;ulink linkID="2100334" linkType="Reference"&gt;2100334&lt;/ulink&gt;]. In January  2019, the BRUDAC voted  18 to 1 in favor of approving the drug, and highlighted a requirement for postmarketing follow-up  [&lt;ulink linkID="2111326" linkType="Reference"&gt;2111326&lt;/ulink&gt;], [&lt;ulink linkID="2111816" linkType="Reference"&gt;2111816&lt;/ulink&gt;]. In April 2019, the FDA approved the drug for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.  The approval included a post-marketing requirement for a five-year observational feasibility study, and potentially a subsequent comparative safety study or trial, to assess the cardiovascular safety of the drug [&lt;ulink linkID="2139632" linkType="Reference"&gt;2139632&lt;/ulink&gt;], [&lt;ulink linkID="2139630" linkType="Reference"&gt;2139630&lt;/ulink&gt;]. In April 2019, the drug was launched in the US [&lt;ulink linkID="2141567" linkType="Reference"&gt;2141567&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2016, data from the  phase III ARCH trial were expected to contribute to a regulatory submission for romosozumab in Europe [&lt;ulink linkID="1790564" linkType="Reference"&gt;1790564&lt;/ulink&gt;], [&lt;ulink linkID="1790567" linkType="Reference"&gt;1790567&lt;/ulink&gt;]. By January 2018, an MAA had been filed  for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, based on data from the  FRAME, ARCH and BRIDGE trials; at that time, the  filing was accepted for review  by the EMA [&lt;ulink linkID="1995572" linkType="Reference"&gt;1995572&lt;/ulink&gt;].In September 2018, the EMA's CHMP adopted a list of outstanding issues with a specific timetable [&lt;ulink linkID="2097419" linkType="Reference"&gt;2097419&lt;/ulink&gt;]. In November 2018, the EMA's CHMP adopted a second list of outstanding issues with a specific timetable and agreed to consult an ad-hoc expert group [&lt;ulink linkID="2109342" linkType="Reference"&gt;2109342&lt;/ulink&gt;]. In February 2019, the EMA's CHMP adopted a third list of outstanding issues with a specific timetable [&lt;ulink linkID="2145916" linkType="Reference"&gt;2145916&lt;/ulink&gt;]. In June 2019, the CHMP adopted a negative opinion on the MAA for the treatment of severe osteoporosis; the companies planned to request re-examination [&lt;ulink linkID="2168818" linkType="Reference"&gt;2168818&lt;/ulink&gt;], [&lt;ulink linkID="2169105" linkType="Reference"&gt;2169105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2018, a filing for approval based on the FRAME, ARCH, BRIDGE and STRUCTURE trials had been submitted in Switzerland, presumably for postmenopausal and male osteoporosis [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In December 2016, romosozumab was filed for approval in Japan for the treatment of osteoporosis for those at high risk of fracture, presumably including male osteoporosis and  PMO, based on data from FRAME and BRIDGE [&lt;ulink linkID="1886951" linkType="Reference"&gt;1886951&lt;/ulink&gt;]. In July 2018, the filing submitted to the PMDA was under review [&lt;ulink linkID="2053645" linkType="Reference"&gt;2053645&lt;/ulink&gt;]. In November 2018, the First Committee on New Drugs PAFSC would discuss the approval of romosozumab in Japan for osteoporosis in a meeting scheduled on December 3, 2018 [&lt;ulink linkID="2097112" linkType="Reference"&gt;2097112&lt;/ulink&gt;]. In December 2018, the PASFC recommended the drug for approval; at that time, approval was expected by the end of the year [&lt;ulink linkID="2102881" linkType="Reference"&gt;2102881&lt;/ulink&gt;]. In January 2019, the drug was approved in Japan for the treatment of patients with osteoporosis at high risk of fracture [&lt;ulink linkID="2109283" linkType="Reference"&gt;2109283&lt;/ulink&gt;], [&lt;ulink linkID="2109739" linkType="Reference"&gt;2109739&lt;/ulink&gt;]. In March 2019, the drug was launched in Japan [&lt;ulink linkID="2125293" linkType="Reference"&gt;2125293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In August 2016, a regulatory filing was submitted and completed for romosozumab for treating women with PMO at increased risk of fracture [&lt;ulink linkID="1886951" linkType="Reference"&gt;1886951&lt;/ulink&gt;], [&lt;ulink linkID="1904138" linkType="Reference"&gt;1904138&lt;/ulink&gt;]. In July 2018, the filing was still under review with Health Canada [&lt;ulink linkID="2064274" linkType="Reference"&gt;2064274&lt;/ulink&gt;]. By June 2019, the drug had been approved in Canada for the treatment of osteoporosis for postmenopausal women at high risk for fracture  [&lt;ulink linkID="2168818" linkType="Reference"&gt;2168818&lt;/ulink&gt;], [&lt;ulink linkID="2169105" linkType="Reference"&gt;2169105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By February 2018, a filing for approval based on the FRAME, ARCH, BRIDGE and STRUCTURE trials had been submitted in Brazil, presumably for postmenopausal and male osteoporosis; at that time, the drug was under regulatory review [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By February 2018, a filing for approval based on the FRAME, ARCH, BRIDGE and STRUCTURE trials had been submitted in Australia, presumably for postmenopausal and male osteoporosis; at that time, the drug was under regulatory review [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2019, the agent was approved in South Korea for postmenopausal osteoporosis and male osteoporosis [&lt;ulink linkID="2127482" linkType="Reference"&gt;2127482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The drug's US label includes a boxed warning regarding the risk of heart attack, stroke and cardiovascular death [&lt;ulink linkID="2139632" linkType="Reference"&gt;2139632&lt;/ulink&gt;], [&lt;ulink linkID="2139630" linkType="Reference"&gt;2139630&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In April 2019, the FDA approved the drug; the approval included a postmarketing requirement for a five-year observational feasibility study, and potentially a subsequent comparative safety study or trial, to assess the cardiovascular safety of the drug [&lt;ulink linkID="2139632" linkType="Reference"&gt;2139632&lt;/ulink&gt;], [&lt;ulink linkID="2139630" linkType="Reference"&gt;2139630&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Osteoporosis&lt;/subtitle&gt;By September 2015, a Japanese phase III trial in osteoporosis had commenced [&lt;ulink linkID="1701204" linkType="Reference"&gt;1701204&lt;/ulink&gt;]; in October 2016, the trial was ongoing [&lt;ulink linkID="1869233" linkType="Reference"&gt;1869233&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Male osteoporosis&lt;/subtitle&gt;In July 2014, multicenter, randomized, double-blind, placebo-controlled phase III trial (&lt;ulink linkID="203762" linkType="Protocol"&gt;NCT02186171&lt;/ulink&gt;; 20110174, 2013-005551-32; BRIDGE) was initiated in the US and Japan to evaluate the safety and efficacy of romosozumab in men (expected n = 225) with osteoporosis [&lt;ulink linkID="1576750" linkType="Reference"&gt;1576750&lt;/ulink&gt;], [&lt;ulink linkID="1577037" linkType="Reference"&gt;1577037&lt;/ulink&gt;]. In March 2016, positive topline data from the 245-patient trial were reported. The primary endpoint was met showing a bone mineral density (BMD) increase at the lumbar spine in the romosozumab-treated patients compared with placebo at 12 months. At that time, an additional analysis of the trial was ongoing  [&lt;ulink linkID="1744900" linkType="Reference"&gt;1744900&lt;/ulink&gt;], [&lt;ulink linkID="1745501" linkType="Reference"&gt;1745501&lt;/ulink&gt;]. In April 2016, the trial was completed [&lt;ulink linkID="1577037" linkType="Reference"&gt;1577037&lt;/ulink&gt;]. In November 2016, similar results were presented at the 2016 ACR Annual Meeting in Washington, DC; romosozumab treatment  led to an increase in P1NP (86% median increase from baseline peaking at 1 month), and a decrease in CTX (31% median decrease from baseline at 1 month) [&lt;ulink linkID="1873704" linkType="Reference"&gt;1873704&lt;/ulink&gt;], [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. In June 2018, results were published. Mean percentage change from baseline in lumbar spine (LS) and total hip (TH) BMD was significantly higher for romosozumab than placebo (LS: 12.1 versus 1.2%; TH: 2.5 versus -0.5%; p &amp;lt; 0.001) [&lt;ulink linkID="2087585" linkType="Reference"&gt;2087585&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Postmenopausal osteoporosis&lt;/subtitle&gt;In February 2018, a randomized, parallel-assignment, open-label, phase III trial (NCT03432533; 20150120; 2017-003512-40) was initiated in the US, Poland and the UK to assesss the non-inferiority of 6-months treatment with 210 mg romosozumab (90 mg/ml) administered subcutaneously once a month  by a healthcare provider with prefilled syringe or by self-administration with an autoinjector/pen in patients (expected n = 260) with post-menopausal osteoporosis. The primary endpoint was percent change from baseline in BMD at the lumbar spine. The trial was expected to complete in June 2019 [&lt;ulink linkID="2082415" linkType="Reference"&gt;2082415&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, a multicenter, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="262436" linkType="Protocol"&gt;NCT02791516&lt;/ulink&gt;; 20150242) began in South Korean postmenopausal women (n = 60) with osteoporosis, to assess the safety and efficacy of 6 month sc treatment of romosozumab, compared to placebo.  In May 2018, the trial was completed [&lt;ulink linkID="1892571" linkType="Reference"&gt;1892571&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, a double-blind randomized phase III study (&lt;ulink linkID="164628" linkType="Protocol"&gt;NCT02016716&lt;/ulink&gt;) began in the US, Poland and the Czech Republic to evaluate two different formulations of romosozumab in PMO. The primary endpoint was percent change in lumbar BMD. The trial was to enroll 72 patients and complete in February 2015 [&lt;ulink linkID="1546504" linkType="Reference"&gt;1546504&lt;/ulink&gt;]. In March 2015, initial data were expected in 1H16 [&lt;ulink linkID="1642856" linkType="Reference"&gt;1642856&lt;/ulink&gt;]. In January 2016, data from the phase III registration trial expected in 1Q16 [&lt;ulink linkID="1731555" linkType="Reference"&gt;1731555&lt;/ulink&gt;]. In April 2016, pivotal phase III data were expected in 2016 [&lt;ulink linkID="1758178" linkType="Reference"&gt;1758178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, a phase III, randomized, multicenter, double-blind, placebo-controlled trial (&lt;ulink linkID="111458" linkType="Protocol"&gt;NCT01796301&lt;/ulink&gt;; 20080289; STRUCTURE) began in the US, Europe, Argentina, Canada and Colombia in women (n = 436) with PMO previously treated with bisphosphonate therapy using &lt;ulink linkID="15518" linkType="Drug"&gt;teriparatide&lt;/ulink&gt; as the active comparator [&lt;ulink linkID="1614061" linkType="Reference"&gt;1614061&lt;/ulink&gt;], [&lt;ulink linkID="1519746" linkType="Reference"&gt;1519746&lt;/ulink&gt;]. In September 2015, the trial met its primary endpoint, demonstrating a  significant difference in the percent change from baseline in total hip BMD through month 12 in patients treated with  romosozumab compared with  teriparatide; at that time, analysis of the results was ongoing  [&lt;ulink linkID="1690834" linkType="Reference"&gt;1690834&lt;/ulink&gt;]. In April 2016, further clinical data were presented at the 98th Endocrine Society Annual Meeting in Boston, MA. Compared with teriparatide, romosozumab was found to be well tolerated and was associated with significant BMD gains at both hip and spine in subjects transitioning from bisphosphonate therapy. Among the treatment groups incidences of treatment emergent adverse events (AEs) and AEs of interest were reported to be balanced [&lt;ulink linkID="1744596" linkType="Reference"&gt;1744596&lt;/ulink&gt;] [&lt;ulink linkID="1748096" linkType="Reference"&gt;1748096&lt;/ulink&gt;]. In May 2016, similar clinical data were presented at the 43rd European Symposium on Calcified Tissues in Rome, Italy  [&lt;ulink linkID="1894906" linkType="Reference"&gt;1894906&lt;/ulink&gt;]. In June 2016, further data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Romosozumab had significantly larger total hip  BMD changes at months 6 (2.3%) and 12 (2.9%), compared to teriparatide (−0.8 and −0.5%, respectively). At months 6 and 12 significantly larger BMD gains at the lumbar spine were observed with romosozumab (7.2 and 9.8%, respectively) compared to teriparatide (3.5 and 5.4%, respectively). Significantly greater gains at months 6 and 12 in integral and cortical BMD with romosozumab versus teriparatide were observed by quantitative computed tomography assessments of the hip [&lt;ulink linkID="1767397" linkType="Reference"&gt;1767397&lt;/ulink&gt;]. In November 2016, similar results were presented at the 80th ACR Annual Meeting in Washington DC [&lt;ulink linkID="1874084" linkType="Reference"&gt;1874084&lt;/ulink&gt;]. In July 2017, further results were published; the mean percentage change from baseline in total hip areal BMD was 2.6 and -0.6% in the romosozumab and  teriparatide groups, respectibely (difference 3.2%; p&amp;lt;0·0001). The frequency of adverse events was generally balanced between treatment groups. There were 6   romosozumab-treated patients versys 12  teriparatide-treated subjects  with adverse events leading to investigational product withdrawal [&lt;ulink linkID="2048295" linkType="Reference"&gt;2048295&lt;/ulink&gt;]. In March 2018, further clinical data were presented at the 100th Endocrine Society Annual Meeting in Chicago, IL. In total, 95 and 91% patients of romosozumab- and teriparatide-treated patients had an increase in P1NP  (total procollagen type 1 N-terminal propeptide) from baseline &amp;gt;/= 10 microg/l at month 1 [&lt;ulink linkID="2015005" linkType="Reference"&gt;2015005&lt;/ulink&gt;].In May 2018, further data were presented at the 45th European Symposium on Calcified Tissues in Valencia, Spain. Of patients having an increase in P1NP from baseline, 91 versus 66% of patients, respectively, had an increase in lumbar spine BMD of &amp;gt; /= 3% at 12 month (82 versus 52% at month 6). Total hip BMD increased by &amp;gt;/= 3% with romosozumab versus teriparatide in 46 versus 18% of women, respectively, at 12 month (38 versus 10% at 6 month). Overall, results suggest that P1NP might be a more reliable indicator of a positive BMD response in romosozumab-treated versus teriparatide-treated women [&lt;ulink linkID="2104289" linkType="Reference"&gt;2104289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, a 2-year, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group-assignment, phase  III trial (&lt;ulink linkID="88820" linkType="Protocol"&gt;NCT01631214&lt;/ulink&gt;; 20110142; 2011-003142-41; ARCH) began in the US, South America, Central America, Europe, Canada, Hong Kong, Israel, South Korea, New Zeland, South Africa, Taiwan and Turkey, which would treat patients with PMO with either romosozumab or &lt;ulink linkID="2472" linkType="Drug"&gt;alendronate&lt;/ulink&gt; for 12 months, followed by open-label alendronate for 12 months in both arms. The primary endpoint was the incidence of new vertebral fractures at 24 months. The trial was to enroll a high-risk  patient poplulation  with a hip BMD T-score of &amp;lt;/= - 2.5 standard deviations (SD) and a vertebral fracture or a hip BMD T-score of &amp;lt;/= - 2.0 SD and a recent hip fracture or two vertebral fractures and complete in November 2017 [&lt;ulink linkID="1678460" linkType="Reference"&gt;1678460&lt;/ulink&gt;]. In May 2017, data were reported from 4093 randomized patients showing that romosozumab met its primary endpoints at 24 months, with a 50% relative risk reduction in new vertebral fractures and a  27% relative risk reduction in clinical fracture (non-vertebral fracture and clinical vertebral fracture). A key secondary endpoint was met, with a  19% reduction in non-vertebral fractures. However, there was an imbalance in positively adjudicated cardiovascular serious adverse events,  at an incidence of 2.5% in the  romosozumab group compared with 1.9% in the alendronate group at 12 months. At that time, the safety signal was to be assessed as part of the overal benefit:risk profile for the drug  [&lt;ulink linkID="1929292" linkType="Reference"&gt;1929292&lt;/ulink&gt;]. In June 2017, the trial was completed [&lt;ulink linkID="1678460" linkType="Reference"&gt;1678460&lt;/ulink&gt;]. In September 2017, similar data were published [&lt;ulink linkID="1960844" linkType="Reference"&gt;1960844&lt;/ulink&gt;], [&lt;ulink linkID="1961217" linkType="Reference"&gt;1961217&lt;/ulink&gt;].  Later that month, further clinical data were presented at the 2017 ASBMR Annual Meeting in Denver, CO. In alendronate/ alendronate and romosozumab/alendronate groups, the percentage change from baseline in BMD of lumbar spine was 5.0 and 13.7 at month 12, respectively (p &amp;lt; 0.001), and was 7.2 and 15.3 at month 24, respectively (p &amp;lt; 0.001); of total hip was 2.8 and 6.2 at month 12, respectively (p &amp;lt; 0.001), and was 3.5 and 7.2 at month 24, respectively (p &amp;lt; 0.001); and of femoral neck was 1.7 and 4.9 at month 12, respectively (p &amp;lt; 0.001), and was 2.3 and 6.0 at month 24, respectively (p &amp;lt; 0.001). Between groups, the overall adverse events were balanced [&lt;ulink linkID="2000050" linkType="Reference"&gt;2000050&lt;/ulink&gt;]. In November 2017, further data were presented at the 81st ACR Annual Meeting in San Diego, CA. During the open label alendronate period, two romosozumab- and four alendronate-treated patients were positively adjudicated for atypical femur fractures; and one romosozumab- and one alendronate-treated patient for osteonecrosis of the jaw  [&lt;ulink linkID="1978337" linkType="Reference"&gt;1978337&lt;/ulink&gt;], [&lt;ulink linkID="1978555" linkType="Reference"&gt;1978555&lt;/ulink&gt;]. In February 2018, a comprehensive assessment was ongoing to understand the safety signal announced in May 2017 [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. In September 2018, further clinical data were presented at the 2018 ASBMR Annual Meeting in Montreal, Canada. In the first year, the mean total hip (TH) bone mineral density score was increased by 6.2 and 2.8% in romosozumab and alendronate scores, respectively, with increase in T score of 0.31 and 0.15, respectively. At 12 months, the TH T score was found to be associated with one-year nonvertebral (NVT) fracture rate in the open label period [&lt;ulink linkID="2111906" linkType="Reference"&gt;2111906&lt;/ulink&gt;].  In October 2018, further data were presented at 82nd ACR Annual Meeting in Chicago, IL. At one year, mean total hip bone mineral density (BMD) increased by 6.2% for romosozumab and 2.8% for alendronate, with an increase in T-score of 0.31 and 0.15, respectively. During the open-label study, the obtained total hip T-score was associated with the one-year nonvertebral fractures rate, with the association being independent of the drug administered in the first year [&lt;ulink linkID="2084286" linkType="Reference"&gt;2084286&lt;/ulink&gt;]. In April 2019, further data were presented at the 2019 WCOOMD in Paris, France. For romosozumab and alendronate treatment groups, mean total hip BMD increased by 6.2 and 2.8%, respectively, in the first year along with an increase in T-score of 0.31 and 0.15, respectively. In the open-label period, the achieved total hip T-score was associated independently of the drug received in the first year with the one-year nonvertebral fracture rate (p &amp;lt; 0.001), at month 12 [&lt;ulink linkID="2149142" linkType="Reference"&gt;2149142&lt;/ulink&gt;]. Further post hoc analysis data were presented at the same conference.In romosozumab versus alendronate groups, the proportions of patients who achieved improvements in BMD at lumbar spine, total hip and femoral neck were 95.1, 74.1 and 65.6% versus 67.2, 47.2 and 37.6%, respectively (&amp;gt;/= 3% improvements); 91.2, 55.9 and 49.6% versus 47.7, 25.9 and 21.3%, respectively (&amp;gt;/= 5% improvement); and 68.2, 18.0 and 16.7% versus 14.4, 3.1 and 4.3%, respectively (&amp;gt;/= 10% improvement, all p &amp;lt; 0.001). Similarly at 24 months, the proportions of patients who achieved improvements in BMD at lumbar spine, total hip and femoral neck were 94.1, 78.9 and 73.5 versus 78.1, 56.4 and 44.6%, respectively (&amp;gt;/= 3% improvements); 91.2, 63.6 and 56.2 versus 65.9, 34.4 and 26.6%, respectively (&amp;gt;/= 5% improvements); and 74.5, 26.9 and 21.6 versus 29.0, 6.7 and 5.4%, respectively (&amp;gt;/= 10% improvements; all p &amp;lt; 0.001)    [&lt;ulink linkID="2149145" linkType="Reference"&gt;2149145&lt;/ulink&gt;]. Further post hoc   subgroup analysis data of East Asian patients were presented at the same conference. In patients treated with alendronate followed by alendronate or romosozumab followed by alendronate groups, cumulative incidence of new vertebral fractures through 24 months (primary endpoint) was reported in 6.6 and 2.5% of patients (RR of 0.40), respectively, in East Asian population and in 8 and 4.1% of patients (RR of 0.50), respectively, in global population  [&lt;ulink linkID="2149139" linkType="Reference"&gt;2149139&lt;/ulink&gt;]. In May 2019, further data were reported at 46th European Symposium on Calcified Tissues in Budapest, Hungary. At 12 months treatment with romosozumab versus alendronate, total hip (TH) bone mineral density increased by 6.2 versus 2.8%, with an increase of T-score by 0.31 versus 0.15, respectively. An association was reported between 12 months TH T-score and 1-year nonvertebral fracture rate during OL study, which was independent of initial treatment. During OL study, romosozumab-to-alendronate versus alendronate-to-alendronate patients reported 75% (p &amp;lt; 0.001) of lower relative risk of new vertebra fracture, 32% (p = 0.001) reduction in clinical, 19% (p = 0.120) of nonvertebral and 40% (p = 0.041) of hip fractures   [&lt;ulink linkID="2160414" linkType="Reference"&gt;2160414&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In April 2012, a 2-year, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group-assignment, phase III trial, presumed to be the FRAME study (&lt;ulink linkID="86463" linkType="Protocol"&gt;NCT01575834&lt;/ulink&gt;; 20070337; 2011-001456-11)  began in in the US, the UK, Argentina, Australia, Belgium, Brazil, Canada, Colombia, Czech Republic, Denmark, Dominican Republic, Estonia, Germany, Hong Kong, Hungary, India, Japan, Latvia, Lithuania, Mexico, New Zealand, Poland, Romania, Spain and Switzerland, in patients with PMO (n = 7180). The trial would treat patients with romosozumab or placebo for 12 months followed by &lt;ulink linkID="49721" linkType="Drug"&gt;denosumab&lt;/ulink&gt; for 24 months in both arms. The primary endpoint was the incidence of new vertebral fractures at 12  and 24 months. The trial was expected to complete in December 2016. In  December 2016, thetrial was completed [&lt;ulink linkID="1277514" linkType="Reference"&gt;1277514&lt;/ulink&gt;], [&lt;ulink linkID="1493352" linkType="Reference"&gt;1493352&lt;/ulink&gt;]. In January 2014, enrollment was complete [&lt;ulink linkID="1519161" linkType="Reference"&gt;1519161&lt;/ulink&gt;]. In February 2014, it was noted that the sample  population had been increased to approximately 7000 patients [&lt;ulink linkID="1529979" linkType="Reference"&gt;1529979&lt;/ulink&gt;]. In January 2016, the company expected to enroll 7200 patients in the registrational trial  [&lt;ulink linkID="1727701" linkType="Reference"&gt;1727701&lt;/ulink&gt;]. In February 2016, positive topline data from the 7180-patient trial were reported; the FRAME study met the coprimary endpoints by demonstrating a 73% reduction in the relative risk of a new vertebral fracture through months 12 and 24 in postmenopausal women with osteoporosis receiving sc romosozumab monthly compared with placebo  group. Additionally, romosozumab-treated patients experienced a 36% reduction in the relative risk of a clinical fracture through 12 months compared with placebo-treated patients. Further analysis of the FRAME study data and an additional 12-month extension period of open-label 60 mg denosumab sc every 6 months were ongoing [&lt;ulink linkID="1736430" linkType="Reference"&gt;1736430&lt;/ulink&gt;]. At that time, further  data were reported  showing that the results of analyses of biomarkers of bone formation, biomarkers of bone resorption and bone mineral density in the FRAME trial were consistent  with  results  observed previously [&lt;ulink linkID="1743080" linkType="Reference"&gt;1743080&lt;/ulink&gt;]. In September 2016, similar data were presented at the American Society for Bone and Mineral Research annual meeting held in Atlanta, GA [&lt;ulink linkID="1797997" linkType="Reference"&gt;1797997&lt;/ulink&gt;]; in that month, similar data were published [&lt;ulink linkID="2048294" linkType="Reference"&gt;2048294&lt;/ulink&gt;], [&lt;ulink linkID="2008081" linkType="Reference"&gt;2008081&lt;/ulink&gt;]. In November 2016, further clinical data were presented at the 80th ACR Annual Meeting in Washington DC. Patients treated with romosozumab for one year showed persisted vertebral fracture risk reduction through month 24 after both groups transitioned to denosumab (2.5% for placebo + denosumab and 0.6% for romosozumab + denosumab). Clinical fracture risk (secondary endpoint) was reduced at month 12 with romosozumab treatment (1.6%) relative to placebo (2.5%). Non-vertebral fracture incidence through month 12 was 2.1 and 1.6% for placebo and romosozumab, respectively, with a similar risk reduction of 25% (placebo + denosumab versus romosozumab + denosumab) through month 24 [&lt;ulink linkID="1873940" linkType="Reference"&gt;1873940&lt;/ulink&gt;].  In December 2016, the trial was completed [&lt;ulink linkID="1493352" linkType="Reference"&gt;1493352&lt;/ulink&gt;]. In March 2017, further clinical data were presented at the 2017 WCOOMD in Florence, Italy. In subjects who received romosozumab in one year, reduction in new vertebral fracture was persisted through month-24 with relative risk reduction of 75% after receiving denosumab in both groups (2.5 and 0.6% placebo/denosumab and romosozumab/denosumab treated groups, respectively, p &amp;lt; 0.001). During one year, injection site reactions were observed in 2.9 and 5.2% in placebo and romosozumab arms, respectively [&lt;ulink linkID="1924662" linkType="Reference"&gt;1924662&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The risk of clinical vertebral fracture was found to be 83% lower in romosozumab arm compared with placebo at 12 months (p = 0.001) [&lt;ulink linkID="1924663" linkType="Reference"&gt;1924663&lt;/ulink&gt;]. In June 2017, further clinical data were presented at18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Women reporting back pain were 119 and diagnosed with a new or worsening vertebral fracture were 20 over 12 months. Clinical vertebral fracture reported with romosozumab and placebo were 3 (&amp;lt; 0.1%, all at &amp;lt; 2 months) and 17 (0.5% at 12 months), respectively [&lt;ulink linkID="1935573" linkType="Reference"&gt;1935573&lt;/ulink&gt;] [&lt;ulink linkID="1937877" linkType="Reference"&gt;1937877&lt;/ulink&gt;]. In September 2017, the additional 12-month extension period of open-label 60 mg denosumab was  ongoing [&lt;ulink linkID="1960017" linkType="Reference"&gt;1960017&lt;/ulink&gt;]. Later that month, further data were presented at the 2017 ASBMR Annual Meeting in Denver, CO. Despite both treatment groups received denosumab in year two, between groups the treatment with romosozumab resulted in relative risk reductions in fractures during the second year; with 81, 32 and 39% reduction of vertebral, clinical and major osteoporotic fractures, respectively (p &amp;lt; 0.001, 0.052 and 0.034, respectively).  During year two, when patients in both groups received denosumab, romosozumab treated patients achieved a substantially reduction in fracture rates due to one year of romosozumab treatment before transition to denosumab [&lt;ulink linkID="2000062" linkType="Reference"&gt;2000062&lt;/ulink&gt;]. Further 36-month data were presented at the same conference. In placebo/denosumab versus romosozumab/denosumab groups, fracture risk reduction for new vertebral fracture (2.8 versus 1.0%; p &amp;lt; 0.001), clinical fracture (5.5 versus 4.0%; p = 0.004), nonvertebral fracture (4.9 versus 3.9%; p = 0.039), major nonvertebral fracture (3.8 versus 2.8%; p = 0.015), major osteoporotic fracture (4.1 versus 2.9%; p = 0.006), multiple new or worsening vertebral fracture (0.6 versus &amp;lt; 0.1%; p &amp;lt; 0.001), new or worsening vertebral fracture (2.8 versus 1.0%; p &amp;lt; 0.001), clinical new or worsening vertebral fracture (0.7 versus 0.1%; p &amp;lt; 0.001), hip fracture (0.9 versus 0.5; p = 0.071), respectively, were observed. BMD continued to increase in the romosozumab/denosumab group to 18.1% (lumbar spine), 9.4% (total hip) and 8.2% (femoral neck) (all p &amp;lt; 0.001) [&lt;ulink linkID="2000045" linkType="Reference"&gt;2000045&lt;/ulink&gt;]. At the same conference, further data were presented. Compared to month 0, romosozumab treatment for 2 months significantly increased  bone formation rate in cancellous bone (12.5 microm3/microm2/year; p &amp;lt; 0.001) and endocortical bone to (52.3 microm3/microm2/year; p &amp;lt; 0.001). Bone formation rate increased by 328% in romosozumab versus 79% placebo (p=0.007) cancellous bone and 233% versus -34% for endocortical bone (p &amp;lt; 0.001) over this period. At month-2 or 12, romosozumab did not affect cortical bone formation rate, whereas cancellous bone formation rate was decreased at month 12 compared with placebo [&lt;ulink linkID="2000065" linkType="Reference"&gt;2000065&lt;/ulink&gt;]. Further data of Iliac crest bone biopsies were presented at the same conference. At month 2, romosozumab significantly lowered trabecular separation compared to placebo. At month-12,  romosozumab significantly increased parameters reflecting mineral density and bone volume. At month 2 or 12, romosozumab had no effect on cortical BMD and cortical porosity [&lt;ulink linkID="2000067" linkType="Reference"&gt;2000067&lt;/ulink&gt;]. In November 2017, further data were presented at the 81st ACR Annual Meeting in San Diego, CA. In the placebo and romosozumab groups, mean absolute bone mass density change in lumbar spine was 0.4 and 13.1% and in total hip was 0.3 and 6.0%; and mean absolute T-score change in lumbar spine was 0.03 and 0.88% and in total hip was 0.01 and 0.32%, respectively, at 12 months [&lt;ulink linkID="1978264" linkType="Reference"&gt;1978264&lt;/ulink&gt;]. Further clinical data were presented at the same conference. At month 36, in placebo/denosumab versus romosozumab/denosumab groups, the fracture risk reduction for new vertebral fracture (2.8 versus 1.0%), clinical fracture (5.5 versus 4.0%), nonvertebral fracture (4.9 versus 3.9%), major nonvertebral fracture (3.8 versus 2.8%), major osteoporotic fracture (4.1 versus 2.9%), multiple new or worsening vertebral fracture (0.6 versus &amp;lt; 0.1%), new or worsening vertebral fracture (2.8 versus 1.0%), clinical new or worsening vertebral fracture (0.7 versus 0.1%), hip fracture (0.9 versus 0.5), respectively, were observed. Bone mineral density (BMD) continued to increase in the romosozumab/denosumab group to 18.1% (lumbar spine), 9.4% (total hip) and 8.2% (femoral neck). Compared with patients initially on placebo, the mean differences in BMD in patients who received romosozumab in the first 12 months remained significant over the entire 36 months ( p &amp;lt;0.001) [&lt;ulink linkID="1978259" linkType="Reference"&gt;1978259&lt;/ulink&gt;] [&lt;ulink linkID="1978555" linkType="Reference"&gt;1978555&lt;/ulink&gt;]. In April 2018, further data were presented at the 2018 WCOOMD in Krakow, Poland. At month 24, after both treatment groups had also received denosumab, mean LS T-score increased by 1.11 and 0.38 for romosozumab / denosumab and placebo/ denosumab, respectively [&lt;ulink linkID="2064387" linkType="Reference"&gt;2064387&lt;/ulink&gt;].  At the same conference, further clinical data were presented. From 0 to 2 months, BFR increase in cancellous bone (p = 0.007) and endocortical bone (p &amp;lt; 0.001) was 328 and 233% (romosozumab) compared with 79 and – 34% (placebo), respectively. At 2 and 12 months, resorption indices were found to be significantly decreased in cancellous and endocortical bone with romosozumab versus placebo [&lt;ulink linkID="2064388" linkType="Reference"&gt;2064388&lt;/ulink&gt;]. In May 2018, further clinical data were presented at the 45th European Symposium on Calcified Tissues in Valencia, Spain. Romosozumab treatment for 12 month led to an early, significant bone-forming effect associated with a sustained decreased bone resorption; these effects were associated with increased bone mass and improved microarchitecture [&lt;ulink linkID="2104290" linkType="Reference"&gt;2104290&lt;/ulink&gt;]. In April 2019, post hoc analysis data were presented from THE first year of the FRAME study at the 2019 WCOOMD in Paris, France. In the first year of romosozumab treatment, the incidences of all fracture outcomes were reduced when compared to placebo, ranging from a 32% reduction in major osteoporotic fracture (MOF) to an 80% reduction in clinical vertebral fractures (p = 0.038). romosozumab treatment led to a decrease in clinical fractures at the 25th and 75th centile of FRAX probability by 22 and 41%, respectively; however, reduced vertebral fractures by a similar extent regardless of baseline risk [&lt;ulink linkID="2149141" linkType="Reference"&gt;2149141&lt;/ulink&gt;]. In June 2019, similar data were published [&lt;ulink linkID="2168020" linkType="Reference"&gt;2168020&lt;/ulink&gt;], [&lt;ulink linkID="2168031" linkType="Reference"&gt;2168031&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2014, data from a phase II, multicenter, international, randomized, placebo-controlled study were presented at the Annual Meeting of the ASBMR in Houston, TX.​  In subjects who received romosozumab (210 mg, sc once-monthly; n = 50), teriparatide (20 microg, sc, qd; n = 49) or placebo (n = 50), at month 12, cortical thickness and apparent cortical BMD was significantly improved with romosozumab when compared with teriparatide and placebo (p &amp;lt;/= 0.0003). Similar improvement in cancellous BMD was observed with both romosozumab and teriparatide. An increase by 43, 17 and 3% in deconvolved segmentation-based cortical thickness was observed with romosozumab, teriparatide and placebo, respectively [&lt;ulink linkID="1592528" linkType="Reference"&gt;1592528&lt;/ulink&gt;]. In April 2019, further data were presented at the 2019 WCOOMD in Paris, France. By one year, an increase was observed in mean vertebral cortical thickness, cancellous BMD and endocortical thickness with romosozumab treatment versus teriparatide (10.3 versus 4.3%, p = 0.000099; 22.7 versus 16.9%, p = 0.035, and 37.2 versus 12.3%, p = 0.000081). Cortical maps showed the precise topographical locations of the increase in bone compared with placebo; in fracture-prone areas of the vertebral shell, walls and endplates.  In the placebo group, a significant decrease in cancellous BMD (-3.4%) was observed [&lt;ulink linkID="2149134" linkType="Reference"&gt;2149134&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2013, a randomized, double-blind, placebo-controlled, multi-dose phase II trial (&lt;ulink linkID="161686" linkType="Protocol"&gt;NCT01992159&lt;/ulink&gt;; 20101291) was initiated in Japan to evaluate efficacy, safety and tolerability of romosozumab in patients (n = 252) with PMO. The trial was expected to be completed in January 2015 [&lt;ulink linkID="1576750" linkType="Reference"&gt;1576750&lt;/ulink&gt;], [&lt;ulink linkID="1577051" linkType="Reference"&gt;1577051&lt;/ulink&gt;]. In October 2015, clinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA. The percentage change from baseline in BMD at month 12 (primary endpoint) was significantly achieved with all romosozumab doses when compared with placebo at each of the three skeletal sites of lumbar spine (LS), total hip (TH) or femoral neck (FN). The highest improvements were observed with romosozumab 210 mg, which showed BMD gains from baseline of 16.9% and 4.7% at the LS and TH, respectively, and 3.8% at the FN. Overall, romosozumab was generally well tolerated [&lt;ulink linkID="1703061" linkType="Reference"&gt;1703061&lt;/ulink&gt;]. In November 2015, further clinical data    were presented at the 79th ACR Annual Meeting in San Francisco, CA. The percent change from baseline to month 6 and 12 in LS BMD was 13.1 and 16.9%; TH BMD was 3.2 and 4.7%;  FN BMD was 3.3 and 3.8%, respectively. Hypocalcemia, hypersensitivity, injection site reactions, osteoarthritis were some of the adverse events of interest [&lt;ulink linkID="1709149" linkType="Reference"&gt;1709149&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2009, a randomized, placebo-controlled, double-blind, multi-dose phase II trial (&lt;ulink url="NCT00896532"&gt;NCT00896532&lt;/ulink&gt;; 20060326) to determine the efficacy, safety and tolerability of romosozumab in the treatment of PMO was scheduled to begin in June 2009 in women with low BMD (expected n = 400). Patients were to receive varying doses of sc romosozumab at either monthly or three monthly intervals with  &lt;ulink linkID="15518" linkType="Drug"&gt;teriparatide&lt;/ulink&gt; or &lt;ulink linkID="2472" linkType="Drug"&gt;alendronate&lt;/ulink&gt; as active comparators. At that time, the trial was estimated to complete in August 2012 [&lt;ulink linkID="1029710" linkType="Reference"&gt;1029710&lt;/ulink&gt;]. By July 2009, the trial had been initiated  [&lt;ulink linkID="1030063" linkType="Reference"&gt;1030063&lt;/ulink&gt;].   Results were reported in April 2011 showing the trial had met the primary endpoint and romosozumab treatment had significantly increased BMD  after 12 months compared with placebo. The drug was also comparable to teriparatide and alendronate and adverse events between groups were also similar  [&lt;ulink linkID="1185507" linkType="Reference"&gt;1185507&lt;/ulink&gt;]. In October 2012, data at 12 months were presented from 419 patients enrolled in the trial at the 2012 ASBMR meeting in Minneapolis, MN. Romosozumab treatment led to rapid, progressive and marked increases in BMD, with a clear dose-responsive effect. The largest gains were observed with 210-mg monthly romosozumab, which led to a significant 11.3% at the lumbar spine improvement in absolute BMD compared with 7% for teriparatide; the difference was significant from the end of the third month [&lt;ulink linkID="1330188" linkType="Reference"&gt;1330188&lt;/ulink&gt;], [&lt;ulink linkID="1331452" linkType="Reference"&gt;1331452&lt;/ulink&gt;]; in June 2013, similar data were presented at the EULAR 2013 Annual Meeting in Madrid, Spain. Further, in 210 mg monthly cohort, the percentage increase in BMD from baseline was 4.1% at the total hip [&lt;ulink linkID="1439295" linkType="Reference"&gt;1439295&lt;/ulink&gt;]. In October 2013, 82  postmenopausal women at the 2013 ASBMR meeting in Baltimore, MD, USA. Significant increase in quantitative computed tomography  integral density and mass at the total hip by 12 months was observed with romosozumab when compared with placebo and teriparatide [&lt;ulink linkID="1483040" linkType="Reference"&gt;1483040&lt;/ulink&gt;], [&lt;ulink linkID="1484499" linkType="Reference"&gt;1484499&lt;/ulink&gt;]. In October 2013, further data were presented from an international  study at the 77th ACR/ARHP Annual Meeting in San Diego CA. At 12 months, romosozumab significantly increased the integral volumetric BMD and bone mineral content at the total lumbar spine (LS)  from baseline versus teriparatide and placebo.  The percentages of cortical vBMD and cortical BMC gain was higher with romosozumab versus teriparatide [&lt;ulink linkID="1493833" linkType="Reference"&gt;1493833&lt;/ulink&gt;]. In January, 2014, similar data were published. In addition, treatment with romosozumab (210-mg monthly) significantly increased BMD at the lumbar spine and total hip compared with alendronate   [&lt;ulink linkID="1512283" linkType="Reference"&gt;1512283&lt;/ulink&gt;], [&lt;ulink linkID="1512466" linkType="Reference"&gt;1512466&lt;/ulink&gt;]. In April 2014, similar data were presented at the 2014 WCOOMD in Seville, Spain [&lt;ulink linkID="1579389" linkType="Reference"&gt;1579389&lt;/ulink&gt;].  In June 2014, similar data were presented at EULAR 2014 Annual Meeting in Paris, France [&lt;ulink linkID="1565521" linkType="Reference"&gt;1565521&lt;/ulink&gt;]. In September 2014,  further data were presented from 56 postmenopausal women with low BMD at the Annual Meeting of the ASBMR in Houston, TX.​  The percentage change in cortical thickness from baseline was 5.6, 11.5 and 0.5% for teriparatide, romosozumab and placebo, respectively [&lt;ulink linkID="1592489" linkType="Reference"&gt;1592489&lt;/ulink&gt;], [&lt;ulink linkID="1593988" linkType="Reference"&gt;1593988&lt;/ulink&gt;]. Further similar data were presented at the same conference [&lt;ulink linkID="1592504" linkType="Reference"&gt;1592504&lt;/ulink&gt;]. In November 2014, further data were presented at the 78th ACR Annual Meeting in Boston, MA. Treatment with romosozumab, rapidly and markedly increased BMD in lumbar spine (15.7%) and total hip (6%), rapidly stimulated P1NP and decreased bone reabsorption compared with &lt;ulink linkID="49721" linkType="Drug"&gt;denosumab&lt;/ulink&gt; or placebo [&lt;ulink linkID="1608622" linkType="Reference"&gt;1608622&lt;/ulink&gt;]. Further data from the high-resolution quantitative CT (HR-QCT) analysis of the trial were presented at the same conference. Cortical thickness, cortical bone mineral content, and apparent cortical BMD were improved by romosozumab at month 12 compared with teriparatide and placebo. Cancellous BMD improvements were similar in romosozumab and teriparatide groups [&lt;ulink linkID="1611902" linkType="Reference"&gt;1611902&lt;/ulink&gt;]. In March 2015, further  data were presented at the 2015 WCOOMD in Milan, Italy. Adverse events (except injection site reaction) were balanced between the romosozumab and placebo groups during the first two years of the study and during year three [&lt;ulink linkID="1651392" linkType="Reference"&gt;1651392&lt;/ulink&gt;]. In June 2015, further data were presented at the 16th EULAR Annual European Congress in Rome, Italy. Patients treated  with romosozumab reported increase in BMD and patients who followed up with denosumab after receiving romosozumab for two years continued to show increased BMD at a rate similar to that of the second year treatment of romosozumab when compared with the patients who followed up with placebo, in whom the BMD returned to pretreatment levels [&lt;ulink linkID="1667642" linkType="Reference"&gt;1667642&lt;/ulink&gt;]. In October 2015, exploratory sub-study data from the 419-patient study were presented at the American Society for Bone and Mineral Research 2015 Annual Meeting in Seattle, WA. At 12 months, romosozumab increased estimated bone strength in postmenopausal women with low bone mass by more than teriparatide, as measured by finite element analysis (FEA). Change from baseline in estimated bone strength at the spine was +27.3, +18.5 and -3.9% for the romosozumab, teriparatide and placebo, respectively; change in estimated bone strength at the hip was +3.6, -0.7 and -0.1% for the three groups, respectively [&lt;ulink linkID="1706147" linkType="Reference"&gt;1706147&lt;/ulink&gt;]. At the same conference, further data were presented.  At month 12, romosozumab increased strength at the spine, from baseline by 27.3%, compared with placebo (–3.9%) and teriparatide (18.5%) [&lt;ulink linkID="1703051" linkType="Reference"&gt;1703051&lt;/ulink&gt;], [&lt;ulink linkID="1702670" linkType="Reference"&gt;1702670&lt;/ulink&gt;]. In November 2015, similar  data were presented at the 79th ACR Annual Meeting in San Francisco, CA. Estimated strength by FEA at the hip was increased by romosozumab at 12 months at cortical and trabecular compartments at the both sites [&lt;ulink linkID="1710161" linkType="Reference"&gt;1710161&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 99th Endocrine Society Annual Meeting in Orlando, FL. Following treatment with romosozumab, a reduction in BMD to slightly above (lumbar spine) or below (hip) baseline was observed in the no active treatment group (prior treatment with romosozumab); while treatment with single dose zoledronic acid generally maintained the BMD gains achieved at the lumbar spine and hip for 12 months. In the follow-up period, no new safety signals were observed and no increase in fragility fractures was reported between the two arms [&lt;ulink linkID="1913227" linkType="Reference"&gt;1913227&lt;/ulink&gt;], [&lt;ulink linkID="1913401" linkType="Reference"&gt;1913401&lt;/ulink&gt;]. Further data were presented at the same conference. Retreatment with romosozumab from months 36 to 48 after placebo led to BMD increases by 12.7, 5.8 and 6.3% at the LS, TH, and FN, respectively, which were comparable to the initial romosozumab treatment. Between baseline and 24 months, safety profile of romosozumab retreatment appeared to be generally consistent with romosozumab treatment [&lt;ulink linkID="1913156" linkType="Reference"&gt;1913156&lt;/ulink&gt;], [&lt;ulink linkID="1913401" linkType="Reference"&gt;1913401&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;By February 2007, the drug was in phase I trials [&lt;ulink linkID="769790" linkType="Reference"&gt;769790&lt;/ulink&gt;]. In October 2007, data were presented at the 13th International HAH Conference in Milan, Italy. A 200% increase in P1NP   was seen with 10 mg/kg of romosozumab at day 28 post treatment   [&lt;ulink linkID="848126" linkType="Reference"&gt;848126&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2012, data from a double-blind, placebo-controlled, randomized, ascending multiple dose study in healthy men and postmenopausal women (n = 48) were presented at EULAR 2012 in Berlin, Germany. There was an approximate dose proportional increase in the mean serum romosozumab exposures across the q2w and q4w dose ranges in both men and women. Significant increase in lumbar spine BMD from baseline was observed with romosozumab. Neutralizing antibodies were developed in two subjects with no discernable effects on pharmacokinetics, pharmacodynamics, or safety [&lt;ulink linkID="1296275" linkType="Reference"&gt;1296275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Fracture healing&lt;/subtitle&gt;By May 2009, a randomized, placebo-controlled phase II trial  (&lt;ulink url="NCT00907296"&gt;NCT00907296&lt;/ulink&gt;) of sc romosozumab was planned in adults with a fresh unilateral tibial diaphyseal fracture following a  fracture fixation with an intramedullary nail. The primary hypothesis for this study was efficacy in reducing radiographic healing time. The trial began in July 2009, and was expected to complete in November 2012 and enroll 400 patients [&lt;ulink linkID="1017284" linkType="Reference"&gt;1017284&lt;/ulink&gt;].    In October 2010, first results were expected in  2012 [&lt;ulink linkID="1141195" linkType="Reference"&gt;1141195&lt;/ulink&gt;]. In October 2012, data were expected in 1H13 [&lt;ulink linkID="1334071" linkType="Reference"&gt;1334071&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2016, preclinical data were presented at the 2016 ASBMR Annual Meeting in Atlanta, GA. In ovariectomized cynomolgus monkeys, treatment with romosozumab (3 mg/kg, qw, sc) showed a significant reduction in cortical tissue bone mineral density in the radial diaphysis and metaphysis at week 25 [&lt;ulink linkID="1802032" linkType="Reference"&gt;1802032&lt;/ulink&gt;].  Further preclinical data were presented at the same conference. Romosozumab blocked the binding of sclerostin to the extracellular domains (ECDs) of lipoprotein receptor-related protein (LRP)5 and LRP6, but did not block the binding of sclerostin to the ECD of LRP4 [&lt;ulink linkID="1802114" linkType="Reference"&gt;1802114&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, preclinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA.  Stiffness associated with HLS or OVX+HLS was prevented with Scl-Ab. Ultimate load was significantly greater in Scl-Ab-treated HLS or OVX rats but not significantly lower HLS, OVX or OVX+HLS as compared with Sham controls [&lt;ulink linkID="1703301" linkType="Reference"&gt;1703301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, preclinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA. A progressive increase in bone volume (BV/TV) was observed through day 183 with teh antibody treatment (end of treatment) and gradually declined thereafter, in L4 vertebrae [&lt;ulink linkID="1703311" linkType="Reference"&gt;1703311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, preclinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA. Romosozumab did not increase osteoclastic surface in comparison with PTH (1-34). BFR/BS was similar with both romosozumab and PTH (1-34), after 26 weeks [&lt;ulink linkID="1703308" linkType="Reference"&gt;1703308&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, preclinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA. The projected final wall thickness for completing remodeling packets was significantly increased with romosozumab by 52% (57 versus 37 mm in vehicle) [&lt;ulink linkID="1703304" linkType="Reference"&gt;1703304&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, preclinical data were presented at the 2015 ASBMR Annual Meeting in Seattle, WA. Romosozumab treatment (3 or 30 mg/kg, sc injections) for 12 months in ovariectomized cynomolgus monkeys showed notable improvements in bone mass, cortical geometry and bone strength and also maintained bone quality [&lt;ulink linkID="1703057" linkType="Reference"&gt;1703057&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, preclinical data were presented at the 2013 ASBMR meetin in Baltimore, MD, USA. In female Sprague dawley rats, treatment with romosozumab (50 mg/kg) dose-dependently increased bone mass throughout the skeleton. At all dose levels (10, 30 and 50 mg/kg), romosozumab increased cortical thickness when compared with control animals. Treatment with romosozumab improved ultimate strength and toughness, whereas the elastic modulus was not affected [&lt;ulink linkID="1483245" linkType="Reference"&gt;1483245&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, data were presented at the American Society for Bone and Mineral Research Annual Meeting in Philadelphia, PA,  showing that  the agent increased bone mineral content. The antibody was administered at 3, 10 and 30 mg/kg doses once-monthly over 2 months to female cynomolgus monkeys. There was a 5.5-fold increase in the rate of bone formation in lumbar vertebrae for the antibody-treated 30 mg/kg dose group in the first month, compared to the control group, and after 2 months the strength of lumbar vertebrae increased for this dose group. At that time,  safety and efficacy data were to become available when clinical trials were underway [&lt;ulink linkID="691608" linkType="Reference"&gt;691608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2006, romosozumab was in accelerated studies [&lt;ulink linkID="647730" linkType="Reference"&gt;647730&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, Amgen and Celltech identified a high-affinity function modifying Celltech's antibody for further study [&lt;ulink linkID="510650" linkType="reference"&gt;510650&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By October 2002, studies in transgenic mice confirmed that overexpression of sclerostin led to weak bones. Target validation studies showed that a loss of sclerostin results in strong bones and that sclerostin-neutralizing antibodies inhibit mineralization in stem cell cultures. Furthermore, the Rotterdam elderly study of 10,000 patients over 55 years of age showed that polymorphism in the SOST gene region provided a link to human osteoporosis [&lt;ulink linkID="469064" linkType="reference"&gt;469064&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2002, the program was in late stage research involving target validation and antibody generation activities [&lt;ulink linkID="451519" linkType="reference"&gt;451519&lt;/ulink&gt;], [&lt;ulink linkID="490277" linkType="reference"&gt;490277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The results of genetic analysis studies were published in 2001. Homozygosity mapping in Afrikaner families combined with analysis of historical recombinants localized sclerosteosis to an interval between the loci D17S1787 and S17S930 on chromosome 17q12-q21. Two independent mutations were found in the gene termed SOST. Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cysteine knot containing factors including dan, cerberus, gremlin, prdc, and caronte. These results suggested that the SOST gene encodes an important new regulator of bone homeostasis [&lt;ulink linkID="444859" linkType="reference"&gt;444859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 1999, sclerostin had been identified through the analysis of a rare genetic defect observed in sclerosteosis patients, which results in extreme bone growth [&lt;ulink linkID="300874" linkType="reference"&gt;300874&lt;/ulink&gt;], [&lt;ulink linkID="325289" linkType="reference"&gt;325289&lt;/ulink&gt;]. The company, alongside the &lt;ulink linkID="30690" linkType="Company"&gt;University of Cape Town&lt;/ulink&gt;, studied the mutation among a small population of Afrikaner patients, consisting of approximately 100 patients and their families. Chiroscience used data from this population to identify the mutant gene from the other genes identified in the area. The identified BEER gene encoded the sclerostin protein which appeared to be involved in bone density regulation [&lt;ulink linkID="300874" linkType="reference"&gt;300874&lt;/ulink&gt;], [&lt;ulink linkID="325289" linkType="reference"&gt;325289&lt;/ulink&gt;], [&lt;ulink linkID="490352" linkType="reference"&gt;490352&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 1999, Chiroscience stated that this project would be a pioneer in its efforts to commercialize drugs against proprietary targets [&lt;ulink linkID="326568" linkType="reference"&gt;326568&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2011, the EMA's pediatric committee (PDCO) recommended that the requirement to submit data from clinical studies in children be waived [&lt;ulink linkID="1249888" linkType="Reference"&gt;1249888&lt;/ulink&gt;]. However, by February 2016, the PDCO had agreed a pediatric investigation plan (PIP) for romosozumab for treatemtn of osteoporosis [&lt;ulink linkID="1735410" linkType="Reference"&gt;1735410&lt;/ulink&gt;]. In June 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to an agreed PIP for osteoporosis [&lt;ulink linkID="2055591" linkType="Reference"&gt;2055591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sclerostin is the protein product of the SOST gene, also known as the  Bone Equilibrium Expression Regulator (BEER) gene [&lt;ulink linkID="451519" linkType="Reference"&gt;451519&lt;/ulink&gt;], [&lt;ulink linkID="490277" linkType="Reference"&gt;490277&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-04-15T00:00:00.000Z</StatusDate><Source id="2141567" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-04T00:00:00.000Z</StatusDate><Source id="2125293" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-05-31T00:00:00.000Z</StatusDate><Source id="2127482" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-06-28T00:00:00.000Z</StatusDate><Source id="2168818" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-05-31T00:00:00.000Z</StatusDate><Source id="2127482" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-08T00:00:00.000Z</StatusDate><Source id="1995572" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-08T00:00:00.000Z</StatusDate><Source id="1995572" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-08T00:00:00.000Z</StatusDate><Source id="1995572" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-02-22T00:00:00.000Z</StatusDate><Source id="2008081" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-08T00:00:00.000Z</StatusDate><Source id="1995572" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-06-23T00:00:00.000Z</StatusDate><Source id="1577037" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1493352" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-11T00:00:00.000Z</StatusDate><Source id="1375281" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15336">UCB Celltech</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-06-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1030063" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1429683" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-09-24T00:00:00.000Z</StatusDate><Source id="1701204" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-09-24T00:00:00.000Z</StatusDate><Source id="1701204" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-06-23T00:00:00.000Z</StatusDate><Source id="1577037" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-01T00:00:00.000Z</StatusDate><Source id="1581119" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-08-01T00:00:00.000Z</StatusDate><Source id="1460967" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1614061" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-09T00:00:00.000Z</StatusDate><Source id="1577037" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-04-04T00:00:00.000Z</StatusDate><Source id="1277514" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-19T00:00:00.000Z</StatusDate><Source id="1886951" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089961">Amgen Astellas BioPharma KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-08T00:00:00.000Z</StatusDate><Source id="2109283" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-07-22T00:00:00.000Z</StatusDate><Source id="1782080" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-04-09T00:00:00.000Z</StatusDate><Source id="2139632" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2548">Male osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-06-23T00:00:00.000Z</StatusDate><Source id="1577037" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-12-31T00:00:00.000Z</StatusDate><Source id="1892571" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-08-31T00:00:00.000Z</StatusDate><Source id="1904138" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20452">UCB SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1614061" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="45">Bone disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-05-17T00:00:00.000Z</StatusDate><Source id="451519" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="45">Bone disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-05-30T00:00:00.000Z</StatusDate><Source id="248274" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15336">UCB Celltech</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="45">Bone disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-28T00:00:00.000Z</StatusDate><Source id="769790" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-04172"><Name>Sclerostin</Name><SwissprotNumbers><Swissprot>Q99P67</Swissprot><Swissprot>Q99P68</Swissprot><Swissprot>Q9BG78</Swissprot><Swissprot>Q9BG79</Swissprot><Swissprot>Q9BQB4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2168818" linkType="reference" linkID="2168818"&gt;2168818&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20452">UCB SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="111584" title="Amgen and UCB Celltech to develop compounds to treat osteoporosis worldwide"></Deal><Deal id="145266" title="Astellas Pharma to codevelop five Amgen drugs in Japan "></Deal></Deals><PatentFamilies><PatentFamily id="1141060" number="WO-2004082608" title="Ligands for TGF--beta binding proteins and uses thereof"></PatentFamily><PatentFamily id="1191084" number="WO-2005003158" title="Compositions and methods for increasing bone mineralization"></PatentFamily><PatentFamily id="1365387" number="WO-2006119062" title="Epitopes"></PatentFamily><PatentFamily id="1633795" number="WO-2011143307" title="High concentration antibody formulations"></PatentFamily><PatentFamily id="1637301" number="WO-2012058393" title="DKK1 antibodies and methods of use"></PatentFamily><PatentFamily id="1857747" number="WO-2012135035" title="Anti-sclerostin antibody crystals and formulations thereof"></PatentFamily><PatentFamily id="2122659" number="WO-03087763" title="Association of polymorphisms in the sost gene region with bone mineral density"></PatentFamily><PatentFamily id="2292240" number="WO-2011049449" title="VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering"></PatentFamily><PatentFamily id="2382585" number="WO-2012145417" title="Method for treating osteoporosis"></PatentFamily><PatentFamily id="2465641" number="WO-2013019954" title="Method for treating bone gap defects"></PatentFamily><PatentFamily id="2478677" number="WO-00032773" title="Compositions and methods for increasing bone mineralization"></PatentFamily><PatentFamily id="2739703" number="WO-2014075185" title="Antimicrobial articles produced by additive manufacturing"></PatentFamily><PatentFamily id="3198870" number="WO-2017153541" title="Pharmaceutical formulation"></PatentFamily><PatentFamily id="3758428" number="WO-2017139741" title="Drug delivery device and method of manufacture"></PatentFamily><PatentFamily id="3834986" number="WO-2017189089" title="Drug delivery device with messaging label"></PatentFamily><PatentFamily id="4379060" number="WO-2019020069" title="SOST antibody pharmaceutical composition and uses thereof"></PatentFamily><PatentFamily id="583433" number="WO-2005014650" title="Antibodies specific for sclerostin and methods for increasing bone mineralization"></PatentFamily><PatentFamily id="622260" number="WO-03073991" title="Methods to increase or decrease bone density"></PatentFamily><PatentFamily id="642428" number="WO-2009079471" title="Method for treating bone fracture with anti-sclerostin antibodies"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Hengrui Medicine Co Ltd" id="1006925"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universiteit Twente" id="1008199"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orthopaedic Innovation Center Inc" id="1096352"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universiteit Utrecht" id="20692"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Erasmus University Rotterdam" id="23277"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>